Vernakalant: A new drug to treat patients with acute onset atrial fibrillation

Cardiology in Review

Volumn 19, Issue 1, 2011, Pages 41-44

  Tian, David ^a   Frishman, William H ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WESTCHESTER MEDICAL CENTER   (United States)

Author keywords

antiarrhythmic; atrial fibrillation; Kv1.5; RSD1235; Vernakalant

Indexed keywords

AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOCHROME P450 INHIBITOR; KYNAPID; PLACEBO; UNCLASSIFIED DRUG; VERNAKALANT;

ACUTE ONSET ATRIAL FIBRILLATION; ARTICLE; BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DYSGEUSIA; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NONHUMAN; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SIDE EFFECT; SNEEZING; TORSADE DES POINTES;

ANISOLES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; CLINICAL TRIALS AS TOPIC; HUMANS; PYRROLIDINES; TREATMENT OUTCOME;

EID: 78650800059     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181f4a6a2     Document Type: Article

References (17)

1. Bilodeau MT, Trotter BW. Kv1.5 Blockers for the treatment of atrial fibrillation: Approaches to optimization of potency and selectivity and translation to in vivo pharmacology. Curr Topic Med Chem. 2009;9:436-451.
2. Cheng J. Vernakalant in the management of atrial fibrillation. Ann Pharmacother. 2008;42:533-542.
3. Naccarelli GV, Wolbrette DL, Samii S, et al. Vernakalant-A promising therapy for conversion of recent-onset atrial fibrillation. Expert Opin Investig Drugs. 2008;17:805-810.
4. Camm AJ, Savelieva I. New anti-arrhythmic drugs for atrial fibrillation: Focus on dronedarone and vernakalant. J Interv Card Electrophysiol. 2008;23:7-14.
5. Orth PM, Hesketh C, Mak CK, et al. RSD1235 blocks late Ina and suppresses early after depolarization and torsades de pointes induced by class III agents. Cardiovasc Res. 2006;70:486-496.
6. Fedida D, Orth PM, Chen JY, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005;16:1227-1238.
7. Astellas Pharma US, Inc. Kynapid, Vernakalant hydrochloride injection. NDA 22-034. Available at: Www.fda.gov/ohrms/dockets/ac/07/briefing/ 2007-4327b1-01-astellas-backgrounder.pdf.
8. Fedida D. Vernakalant (RSD1235): A novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs. 2007;16:519-532.
9. Mao ZL, Wheeler JJ, Clohs L, et al. Pharmacokinetics of novel atrialselective antiarrhythmic agent vernakalant hydrochloride injection (RSD1235): Influence of CYP2D6 expression and other factors. J Clin Pharmacol. 2009;49:17-29.
10. Dorian P, Pinte A, Mangat I, et al. The effect of vernakalant (RSD1235), an investigational anti-arrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol. 2007;50:35-40.
11. Roy D, Rowe BH, Stiell IG, et al. CRAFT Investigators. A randomized, controlled trial of RSD 1235, a novel anti-arrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol. 2004;44:2355-2361.
12. Cardiome Pharma Corp. Vernakalant. Available at: Www.cardiome.com/ vernakalantintravenous.php.
13. Roy D, Pratt CM, Torp-Pedersen C, et al. Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation. A phase 3, randomized, placebo-controlled trial. Circulation. 2008; 117:1518-1525.
14. Kowey PR, Roy D, Mitchell LB, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery. Circ Arrhythm Electrophysiol. 2009;2:652-659.
15. Camm AJ, Capucci A, Hohnloser S, et al. Clinical efficacy and safety of vernakalant compared with amiodarone for intravenous conversion of recent onset atrial fibrillation. Heart Rhythm Society 2010 Scientific Session. May 14, 2010, Denver, Co.
16. Cardiome Pharma Corp. Vernakalant. Available at: Www.cardiome.com/ vernakalantoral.php.
17. Dobrev D, Nattel S. New antiarrhythmic drugs for treatment of atrial fibrillation. Lancet. 2010;375:1212-1223.